



NATIONAL AND KAPODISTRIAN
UNIVERSITY OF ATHENS
MEDICAL SCHOOL
DEPARTMENT OF PNEUMONOLOGY
INTERSTITIAL LUNG DISEASE UNIT



ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΝΟΣΗΜΑΤΩΝ ΘΩΡΑΚΟΣ ΑΘΗΝΩΝ Η ΣΩΤΗΡΙΑ

HOSPITAL FOR DISEASES OF THE CHEST
"SOTIRIA", ΠΑΝΕΠΙΣΤΙΜΙΑΚΗ ΚΛΙΝΙΚΗ

Professor Demosthenes Bouros, MD, PhD, FERS, FCCP, FAPSR
Tel: +30-210-7763557
Mobile: +30-6944757616
Email: debouros@med.uoa.gr, debouros@gmail.com
<http://www.pneumon.org>, www.bouros.org



Professor Demosthenes Bouros, MD, PhD, FERS, FCCP, FAPSR

SHORT CURRICULUM VITAE

Demosthenes Bouros, born in 1951, is a graduate of the Medical School of the Aristotelian University of Thessaloniki (1975) and a PhD of the University of Athens (1988). He was a research fellow at the **Harvard University** in Boston and Visiting Assistant Professor at the **Boston University**. He spent his sabbatical as a Senior Research Associate at the **Royal Brompton Hospital**, and the National Heart and Lung Institute-Interstitial Lung Disease Unit at the **Imperial College** of London, UK (1998-1999). He elected assistant Professor in Pneumology at the Medical School, University of Crete (1989), associate Professor (1995-2002), **Professor of Pneumology** at the **Democritus University of Thrace**, Greece (2002-2014), and **Professor of Pneumology** at the National and Kapodistrian **University of Athens, Greece (2014-)**. Awarded as **Visiting professor** at the Medical University of Vienna by the European Respiratory Society (2010).

He served as vice chair/**chair** of the Department of Pneumology at the University of Crete and the University Hospital of Heraklion, Greece. He also served as director of the Emergency Department, and chairman of the Department of internal medicine at the University Hospital of Heraklion, Crete and member of the **Senate** of the University of Crete. He served as **Professor of Pneumology at the Democritus University of Thrace and head**

of the **Department of Pneumology at the University Hospital of Alexandroupolis**. He also served as **chairman** of the Dept. of Internal Medicine of the University Hospital of Alexandroupolis and chairman of the Dept of Internal Medicine of the Democritus University of Thrace. He organized a **reference centre** for **interstitial lung diseases** and created a national **biobanking** for blood and bronchoalveolar lavage of patients with various forms of interstitial lung diseases.

Currently, he runs the **interstitial lung disease unit (ILDU) of the National and Kapodistrian University of Athens, Medical School**, based in the Hospital for diseases of the Chest "SOTIRIA", which is a reference center for interstitial lung diseases, following more than **2.000 patients** on a regular basis, being a training center for young physicians. In the units lab of **molecular and cellular biology** a number of scientist and clinicians have the opportunity to perform state of the art basic and clinical research in collaborations with national and international renowned centers.

Professor Bouros was **member of the board** of the Medical School of the Democritus University of Thrace, the University Hospital of Alexandroupolis, and the National Council of Health (**KESY**).

He edited a **book** entitled '*Basic principles of clinical pharmacology and therapeutics*' (1999 and 2005 2nd ed.), and is the editor of a book entitled "*Pleural Diseases*" (Marcel Dekker NY, 2004, and 2nd ed, Informa NY, 2009) of the series Lung Biology on Health and Disease published by the NIH (USA).

He has **published >400 articles** in international peer-reviewed journals, has **>12.000 citations, H index 49 (Scopus), H INDEX 62 and citations>17.000 (Google Scholar)**, he wrote >40 chapters in books in Greek and English, is/was member of the **Editorial Board** of many medical journals (**Editor-in-chief** of the bilingual Greek journal *Pneumon*, **Associate Editor**: RESPIRATION, BMC-Pulmonary Medicine, BMC-research notes, Respirology case reports; **Editorial board** member: **LANCET-Respiratory Medicine**, CHEST, **Pulmonary Pharmacology and Therapeutics**, Current Respiratory Medicine Reviews, BMC series, Pulmonary Medicine, WJR, etc.), **reviewer** in many journals (including Lancet, BMJ, AJRCCM, ERJ, Chest, Thorax, PMJ, EJCI, Respir Med, BMC series, Tubercle, ICM), and **member** of many international medical societies. He has been **section editor** for pleural diseases update (Respiration, 2008), interstitial lung diseases (*Current Opinion in Pulmonary Medicine*, 2011 and 2012), Regenerative medicine and stem cells (Respiration 2013) and interstitial lung diseases in connective tissue diseases (Respiration 2015).

He participated in the development of the European Respiratory Society (ERS) official statements for **COPD** (ERJ 1995), **Tuberculosis** management in Europe (ERJ 1999), the new **ATS/ERS/JRS/ALAT guidelines for idiopathic pulmonary fibrosis** (Am J Respir Crit Care Med 2011 and the under publication new ones in 2018) and the ATS/ERS **new classification of idiopathic interstitial pneumonias** (Am J Respir Crit Care Med 2013). Was reviewer of the ERS consensus statement for **lymphangioleiomyomatosis** (ERJ, 2010). He collaborates with many scientists in Europe and the US and is an invited speaker in many scientific conferences.

He is **mentor** of many young physicians and scientists, founder of the *Hellenic interstitial lung diseases group* with many clinical and basic research publications and **president** of the Hellenic **Scientific Society for Rare Diseases and Orphan Drugs**.

He has been elected and served as **National Delegate** of the ERS (1999-2003), member of the **council and the nomination committee** of the ERS (2002-2003), and a member of the **long-range planning committee** of the ATS and the ERS. He served as **auditor** of the ERS (2004-2007) and he is a **member** of the Assembly on Allergy, Inflammation and Immunology (All) Program Committee of the ATS. He is an invited lecturer in many scientific societies internationally.

He elected as a **foundation member of the fellows of the European Respiratory Society (FERS)** and is a **fellow of the American College of Chest physicians (FCCP)** and the **Asian Pacific Society of Respirology (FAPSR)**.

His **main research interests** include the pathophysiologic/pathogenetic mechanisms and treatment of **interstitial lung diseases (idiopathic pulmonary fibrosis) and the pleural diseases**. Among them is the **translational adipose tissue mesenchymal stem cell** research and application in chronic lung diseases, including pulmonary fibrosis and COPD.

Over his more than 30 years clinical career, he participated in more than **40 phase II or III clinical trials** as principal investigator, mainly on interstitial lung diseases, asthma and COPD.

Relevant recent papers

1. Tzouveleakis A, Spagnolo P, Bonella F, Vancheri C, Tzilas V, Crestani B, Kreuter M, **Bouros D**. Patients with **IPF** and lung cancer: diagnosis and management. Lancet Respir Med. 2017 Dec 11. pii: S2213-2600(17)30478-2. doi: 10.1016/S2213-2600(17)30478-2.
2. Bouros E, Filidou E, Arvanitidis K, Mikroulis D, Steiropoulos P, Bamias G, **Bouros D**, Kolios G. Lung fibrosis-associated soluble mediators and bronchoalveolar lavage

- from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts. *Pulm Pharmacol Ther.* 2017 Oct;46:78-87. doi: 10.1016/j.pupt.2017.08.012.
3. Walsh SLF, Maher TM, Kolb M, et al for the **IPF Project Consortium**. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *Eur Respir J.* 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017.
 4. Tomos IP, Tzouveleakis A, Aidinis V, Manali ED, Bouros E, **Bouros D**, Papis SA. Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the 'bed' that counts and not 'the sleepers'. *Expert Rev Respir Med.* 2017 Apr;11(4):299-309. doi: 10.1080/17476348.2017.1300533.
 5. Kishore A, Žižková V, Kocourková L, Petrková J, Bouros E, Nunes H, Loštáková V, Müller-Quernheim J, Zissel G, Kolek V, **Bouros D**, Valeyre D, Petrek M. Association Study for 26 Candidate Loci in Idiopathic Pulmonary Fibrosis Patients from Four European Populations. *Front Immunol.* 2016 Jul 11;7:274. doi: 10.3389/fimmu.2016.00274.
 6. Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. *J Rheumatol.* 2014 Apr;41(4):792-8. doi: 10.3899/jrheum.131251.
 7. Saketkoo LA, Mittoo S, Huscher D, et al for the CTD-ILD Special Interest Group. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax.* 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202. Epub 2013 Dec 24. Erratum in: *Thorax.* 2014 Sep;69(9):834. CTD-ILD Special Interest Group [added]; multiple investigator names added.
 8. Tzouveleakis A, Paspaliaris V, Koliakos G, Ntoliou P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, Kolios G, **Bouros D**. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. *J Transl Med.* 2013 Jul 15;11:171. doi: 10.1186/1479-5876-11-171.

9. Tzouvelekis A, Ntoliou P, Karameris A, Vilaras G, Boglou P, Koulelidis A, Archontogeorgis K, Kaltsas K, Zacharis G, Sarikloglou E, Steiropoulos P, Mikroulis D, Koutsopoulos A, Froudarakis M, **Bouros D**. Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis. *Biomed Res Int*. 2013;2013:654354. doi: 10.1155/2013/654354
10. Drakopanagiotakis F, Xifteri A, Tsiambas E, Karameris A, Tsakanika K, Karagiannidis N, Mermigkis D, Polychronopoulos V, **Bouros D**. Decreased apoptotic rate of alveolar macrophages of patients with idiopathic pulmonary fibrosis. *Pulm Med*. 2012;2012:981730. doi: 10.1155/2012/981730. Epub 2012 Jun 25.
11. Oikonomou N, Mouratis MA, Tzouvelekis A, Kaffe E, Valavanis C, Vilaras G, Karameris A, Prestwich GD, **Bouros D**, Aidinis V. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. *Am J Respir Cell Mol Biol*. 2012 Nov;47(5):566-74. doi: 10.1165/rcmb.2012-0004OC
12. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, **Bouros D**, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med*. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
13. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, **Bouros D**, et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med*. 2013 Sep 15;188(6):733-48. doi: 10.1164/rccm.201308-1483ST.
14. Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, Gibson KF, Konishi K, Yousem SA, Singh M, Handley D, Richards T, Selman M, Watkins SC, Pardo A, Ben-Yehudah A, **Bouros D**, Eickelberg O, Ray P, Benos PV, Kaminski N. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2010 Jul 15;182(2):220-9. doi: 10.1164/rccm.200911-1698OC.
15. Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P, Sotiriou I, Aidinis V, Margaritis D, Tsatalas C, **Bouros D**. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2009 Jun 15;179(12):1121-30. doi: 10.1164/rccm.200812-1936OC.

16. Tzouvelekis A, Aidinis V, Harokopos V, Karameris A, Zacharis G, Mikroulis D, Konstantinou F, Steiropoulos P, Sotiriou I, Froudarakis M, Pneumatikos I, Tringidou R, **Bouros D**. Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis. *Respir Res*. 2009 Feb 27;10:14. doi: 10.1186/1465-9921-10-14.